From the Headache Clinic, Department of Neurology, Soroka Medical Center, Beer-Sheva, Israel (Drs. Ifergane and Wirguin); and Pain and Palliative Care Unit, Division of Community Health, Siaal Research Center for Family Medicine and Primary Care, Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer-Sheva, Israel (Dr. Shvartzman).
Article first published online: 29 MAR 2006
Headache: The Journal of Head and Face Pain
Volume 46, Issue 8, pages 1261–1263, September 2006
How to Cite
Ifergane, G., Wirguin, I. and Shvartzman, P. (2006), Triptans—Why Once?. Headache: The Journal of Head and Face Pain, 46: 1261–1263. doi: 10.1111/j.1526-4610.2006.00435.x
- Issue published online: 29 MAR 2006
- Article first published online: 29 MAR 2006
- Accepted for publication January 18, 2006.
- patient's decision making;
- patient education
Objective.—To evaluate triptan use patterns in a large Israeli HMO district.
Background.—Triptans, 5HT1B/1D agonists, provide an effective and safe relief of headache and accompanying symptoms during an acute migraine attack.
Method.—We retrospectively reviewed the computerized prescription filling data of 1498 patients who filled a first triptan prescription between July 2003 and June 2004.
Results.—During a 1-year follow-up period, 841 patients (56.1%) purchased triptans only once. Single-time users were significantly more prevalent among men and in patients younger than 30 or older than 70 years.
Conclusions.—It seems that many migraine patients choose not to use triptans after their first experience with the drug.